The global tumor ablation market size was estimated at USD 1,037.3 million in 2018 and is expected to grow at CAGR of 11.12% over the forecast period. The increasing prevalence of cancer is the major factor contributing to the market growth. According to the statistics published by the World Health Organization (WHO), nearly 18.1 million cancer cases were newly registered in 2018 and the countries with high human development index have nearly 3 times higher incidence as compared to low-medium index countries, thereby boosting market growth over the forecast period.
Extensive usage of minimally invasive procedures owing to their benefits such as speedy recovery, less trauma, and minimal complications is anticipated to boost the demand for tumor ablation technologies and thereby leading to growth in the market. Research results published by manufacturers, such as Ethicon Endo-Surgery Inc., suggest that MISs are rapidly replacing open/invasive surgeries, owing to factors such as higher patient satisfaction, owing to fewer/or no incision, shorter hospital stay, and fewer postsurgical complications and lower mortality.
According to statistics published by WHO, approximately 8.2 million deaths are recorded each year from cancer, which accounts for 13.0% deaths worldwide. Moreover, a 70.0% increase in the number of cancer cases is anticipated over the next couple of decades. Increasing prevalence is the most promising driver for growth of tumor ablation devices market. Supportive initiatives such as National Cancer Control Programmes (NCCP), which aims to reduce cancer incidence and improve the quality of care, are anticipated to enable access to affordable quality care and thereby, facilitate market growth.
Technological advancements pertaining to accuracy, portability, and cost-effectiveness are expected to serve this market as drivers during the forecast period. Advanced devices, such as image-guided equipment, HIFU, and irreversible electroporation are major examples of these technological advancements. Usage of cooled radiofrequency denervation technique—a procedure that uses radiofrequency thermal energy to ablate sensory nerve fibers of the sacroiliac joint—with internally cooled radiofrequency probes to enlarge size of the lesion is also another example. This technique enables denervation of the sacroiliac joint completely and helps in pain management.
On the basis of technology, the market has been segmented into microwave, radiofrequency, cryoablation and other technologies such as radioiodine, HIFU, laser ablation. Radiofrequency tumor ablation technology held a substantial share in 2018. This can be attributed to the prominent application of this technology in solid tumor removal all over the body and its specificity contributed to its growth. Increasing usage of this technology in solid tumor excision is the prime factor responsible for its lucrative growth. Moreover, the efficiency and specificity of this method is also anticipated to fuel the segment growth
Microwave ablation technology is anticipated to witness remunerative growth over the forecast period owing to benefits offered by this technology. It has various advantages over other techniques, in terms of effectiveness in destroying tumor cells. The benefits of this technology include larger tumor ablation volume, consistency in high temperature, reduced procedural pain, and optimal heating of the cystic mass. These benefits are anticipated to support growth of this segment. Furthermore, minimum procedure time (5-10 minutes), improved efficacy with minimal complications and reduced hospital stay are expected to drive the segment growth.
On the basis of treatment, the tumor ablation market has been segmented into surgical procedures, laparoscopic procedures, and percutaneous procedures. Surgical ablation segment held a substantial share of in 2018, accounting for more than 40% of the market share. Increased prevalence of liver and breast cancer, which require open surgical procedures, are estimated to fuel the segment growth.
Percutaneous ablation segment is expected to exhibit lucrative growth over the forecast period. Rising demand for minimally invasive surgeries is expected to be the main growth driver. These procedures offer faster recovery, decreased scarring, and increased safety. In addition. Factors such as quick surgery time, faster recovery, and patient comfort are anticipated to further boost the segment demand.
However, higher complications associated with it, post-surgical discomfort, and slower recovery are estimated to limit the usage of this procedure.
On the basis of application, the market is segmented into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and others. Other segment includes various types of cancer such as bone metastasis and ENT cancer. Availability of advanced methods and increasing cancer prevalence of are anticipated to facilitate market growth. Liver cancer dominates the market shares in 2018, accounting for nearly 32.78% of the market. This can be attributed to the rising incidence of bile duct cancer as well as primary liver.
Lung cancer has been anticipated to grow at a rapid pace during the forecast period. This can be attributed to the increasing incidence of the disease. For instance, in 2018, lung cancer accounted for nearly 11.6% of total new cancer cases across the globe, meanwhile, Non-Small Cell Lung Cancer (NSCLC) accounted for 85% of all lung cancer cases. Radiofrequency ablation is widely used for the treatment of NSCL and is thereby anticipated to propel the market growth.
North America dominated the overall tumor ablation market with over 34.0% share in 2018. Major factors contributing to the growth of this region include government support for quality healthcare, high purchasing power parity, availability of reimbursement, and increasing prevalence of cancers in the U.S. and Canada. For instance, in the U.S., the Patient Protection and Affordable Care Act (PPACA), promotes quality and affordability of health insurance and reduces the cost of healthcare for individual and government. In addition, precision medicine initiative is formulating the tailored strategies on unique characteristics of diseases. Hence, such government initiatives are anticipated to improve the overall healthcare system, thus boosting the market growth.
Europe accounted for nearly 24.0% share in the global tumor ablation market. A greater extent of public funding in Europe’s healthcare system has contributed to this growth. Moreover, the growing geriatric population coupled with government support to control cancer is estimated to boost the market growth in this region. For instance, the European Cancer Observatory aims to create awareness about cancer, thus facilitating the market demand. Asia Pacific is expected to register the fastest growth rate during the forecast period. Huge population base coupled with economic developments in countries such as India and China open up opportunities for the market players. In addition, with government assistance, the healthcare infrastructure in Asia Pacific is improving. This is anticipated to fuel growth of this region over the forecast period.
Key players of this market are Galil Medical Inc., Misonix Inc., HealthTronics, Angiodynamics, (Covidien), Boston Scientific Corporation, Medtronic Plc. SonaCare Medical, EDAP TMS S.A. and Neuwave Medical Inc. These industry players have adopted various strategies to sustain their position in the market. For instance, New product launches, collaborations, technological advancements, mergers, and acquisitions are the key strategic initiatives in this industry. Similarly, Galil Medical Inc. launched a new family of cryoablation needles, IcePearl 2.1 CX, IceFORCE 2.1CX. The launch of these products is expected to strengthen the company’s product portfolio. Houston Methodist Hospital acquired EDAP's Focal One system in early 2019. This acquisition is based on the positive experience of the hospital post the acquisition of EDAP's Ablatherm system in 2016. Senior Vice President of Operations at the hospital stated that acquiring EDAP's HIFU technology not only benefits patients but also hospital financials.
Base year for estimation
Actual estimates/Historical data
2015 - 2017
2019 - 2026
Revenue in USD Million & CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America, & MEA
U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Thailand, Taiwan, Brazil, Mexico, Argentina, Colombia, South Africa, Saudi Arabia, UAE, Turkey, Israel
Revenue, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research, Inc. has segmented the global tumor ablation market report on the basis of technology, treatment, application, and region:
Technology Outlook (Revenue, USD Million, 2015 - 2026)
Irreversible electroporation ablation
Other ablation technologies
Treatment Outlook (Revenue, USD Million, 2015 - 2026)
Application Outlook (Revenue, USD Million, 2015 - 2026)
Regional Outlook (Revenue, USD Million, 2015 - 2026)
Middle East and Africa (MEA)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
We value your investment and offer free customization with every report to fulfil your exact research needs.
Toll Free: 1-888-202-9519
Email: [email protected]
Phone: +91-20-67491414 (Sales)
Email: [email protected]
Email: [email protected]
Email: [email protected]
Email: [email protected]